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To the Editor: 
The current outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute 
respiratory syndrome coronavirus 2, continues to spread, and as of March 31, 2020, it has 
reached 200 countries, with 785,219 cases and 37,797 deaths (1). Since the first case was 
reported in the Republic of Korea on January 19, 2020, more than 9,500 confirmed cases had 
been identified by March 31. Since March 2, the number of newly-reported cases appeared to 
have been declining, and the reported cases have been mostly related to certain provinces. As 
of March 31, the Republic of Korea (population of 51 million) was testing more than 20,000 
patients per day. Clinical pathologists and microbiologists of other countries wonder how our 
nation rapidly expanded its capacity for COVID-19 testing in such a short period. The key 
factors in this rapid expansion of testing capacity were the establishment of an emergency use 
authorization (EUA) system, an external quality assessment (EQA), and the collaboration 
between the public and private sectors. 
After the Korean outbreak of Middle East Respiratory Syndrome (MERS) in 2015, which 
involved 186 cases including 38 fatalities (2), the Korean Centers for Disease Control and 
Prevention (KCDC), the Korean Society of Laboratory Medicine (KSLM), and the Korean 
Association of External Quality Assessment Service (KEQAS) established the rapid response 
processes for emerging infectious diseases such as an EUA system, similar to that of the U.S. 
FDA (3). In order to control future outbreaks of emerging infectious diseases, a KCDC-
sponsored EQA molecular testing drill for Zika virus and MERS coronavirus was carried out 
by the KEQAS in 2016 in accordance to the established rapid response process (4). The 
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KEQAS developed a system to receive the proficiency test results at that time. On January 16, 
2020, the KSLM launched a COVID-19 Laboratory Response Task Force (LR-TF) to 
facilitate clinical laboratories to establish the diagnostic testing of COVID-19 (Fig. 1). On the 
next day, the KCDC and the KSLM LR-TF had the first meeting on the expansion of 
COVID-19 testing by non-governmental clinical laboratories. The KCDC and the KSLM LR-
TF agreed to cooperate on the training of laboratory personnel, the EQA program, and the 
evaluation of EUA kits for the diagnosis of COVID-19. 
On January 27, the KCDC and the KSLM LR-TF met representatives from domestic 
molecular reagent manufacturers to explain our objective and the schedule of EUA approval 
for COVID-19 molecular diagnostics. By the time, three confirmed COVID-19 cases had 
been reported in Korea. On February 4, the KCDC and the Korean Food and Drug 
Administration (KFDA) approved the PowerChek 2019-nCoV Real-time PCR kit (Kogene 
Biotech, Seoul, Korea) for diagnosis of COVID-19 after co-evaluation by the KCDC and the 
KSLM. For evaluation materials, specimens from the three confirmed individuals were 
triplicated in blind and then serially diluted into four different concentrations. Plasmid DNAs 
containing the E gene and RdRp gene also served as evaluation specimens. The usual 
respiratory pathogen positive samples including coronavirus 229E, NL63, OC43, HKU1 were 
used as negative controls as well as respiratory virus negative specimens. 
On February 5, the proficiency test panel comprised of six plasmid DNAs with varying 
concentrations (one E gene plasmid only, one RdRp gene plasmid only, and four 
concentrations from serial dilution of combined E gene and RdRp gene plasmids) and one 
negative control were shipped on dry ice to the Korean Laboratory Accreditation Program 
(KLAP)-accredited laboratories willing to participate in COVID-19 testing through molecular 
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diagnostics. Delivery to all laboratories including Jeju Island was completed within 10 hours. 
The KEQAS was responsible for transporting the EQA material, collecting the EQA results, 
and judging the results. Only samples with an 80% or more agreement rate compared to the 
expected results were evaluated. Approval for COVID-19 molecular testing was given when 
a laboratory had correctly answered all the evaluable results. By February 6, the KEQAS had 
certified 46 out of the 47 laboratories that entered the results. Forty-six non-governmental 
clinical laboratories were able to begin COVID-19 testing using a commercial EUA kit from 
February 7. Due to high testing demand at the beginning, testing complied with the inclusion 
criteria. The COVID-19 real-time RT-PCR is indicated for confirmation of suspected 
COVID-19 patients who present with fever (37.5  or higher) and/or respiratory symptoms 
(cough, sore throat, etc.) and history of close contact with a confirmed individual within the 
previous 14 days. It is also indicated for screening of asymptomatic individuals in close 
contact with confirmed COVID-19 patients and for differential diagnosis of cases with 
unknown respiratory syndromes (5). There are no specific exclusion criteria for testing, 
although testing done outside the criteria are denied of national healthcare system 
reimbursement for the testing fee. Two more EQAs using the same plasmid DNAs were 
conducted and 49 additional non-governmental clinical laboratories were enrolled. We have 
finished the EQA using the inactivated cultured SARS-CoV-2 spiked into pooled respiratory 
samples. 
As of March 31, a total of 95 non-governmental clinical laboratories are conducting more 
than 20,000 COVID-19 tests per day using five different EUA kits. The five EUA kits’ output 
reached 20,000 kits per week, covering a total of 350,000 clinical samples. 
6 
 
In conclusion, preparedness and rapid implementation of EQA have supported the rapid 
expansion of COVID-19 testing capacity in the Republic of Korea. Owing to the increasing 
diagnostic capacity, our nation was able to slow down the COVID-19 epidemic without 
enforcing city-wide lockdowns or collapse of the national healthcare system. The quality of 
COVID-19 diagnostic testing was ensured by the KLAP and the EQA programs. 
 
Nonstandard abbreviations: EUA, emergency use authorization; EQA, external quality 
assessment; KCDC, Korean Centers for Disease Control and Prevention; KSLM, Korean 
Society of Laboratory Medicine; KEQAS, Korean Association of External Quality 
Assessment Service; KFDA, Korean Food and Drug Administration; KLAP, Korean 
Laboratory Accreditation Program. 
 
Author Contributions: All authors confirmed they have contributed to the intellectual 
content 
of this paper and have met the following 4 requirements: (a) significant contributions to the 
conception and design, acquisition of data, or analysis and interpretation of data; (b) 
drafting or revising the article for intellectual content; (c) final approval of the published 
article; and (d) agreement to be accountable for all aspects of the article thus ensuring that 
questions related to the accuracy or integrity of any part of the article are appropriately 
investigated and resolved. 
All authors contributed to the conception of the correspondence. HS and WKM wrote the 




Author’s Disclosure or Potential Conflicts of Interest: Upon manuscript submission, all 
authors completed the author disclosure form. Disclosures and/or potential conflicts of 
interest: 
 
Consultant or Advisory Role: None declared. 
Stock Ownership: None declared. 
Honoraria: None declared. 
Research Funding: H. Sung, Korea Centers for Disease Control and Prevention and the Bio 
and Medical Technology Development Program of the National Research Foundation (NRT), 
Korea and funded by the Korean government (MSIP and MOHW, grant number NRF-
2016M3A9B6918716). 
Expert Testimony: None declared. 
Patents: None declared. 
 
Role of Sponsors: The funding organizations played no role in the preparation of manuscript 
or final approval of manuscript. 
 
References 
1. https://www.worldometers.info/coronavirus/#countries (assessed Mar 31, 2020). 
2. Korea Centers for Disease Control and Prevention. Middle East Respiratory 
Syndrome coronavirus outbreak in the Republic of Korea, 2015. Osong Public 
Health Res Perspect 2015;6:269-78. 




and-policy-framework/emergency-use-authorization (accessed Mar 31, 2020). 
4. Chang J, Lee HY, Seong MW, Kim MN, Sung H. External quality assessment of 
molecular diagnostics for Zika virus and Middle East Respiratory Syndrome 
coronavirus in Korea. Southeast Asian J Trop Med Public Health 2019;50:840-7. 
5. Hong KH, Lee SW, Kim TS, Huh HJ, Lee J, Kim SY, et al. Guidelines for laboratory 





Figure 1. Timeline of COVID-19 testing-related collaborations between the public 
and the private sectors 
Abbreviations: KSLM, Korean Society of Laboratory Medicine; KCDC, Korean 
Centers for Disease Control and Prevention; KFDA, Korean Food and Drug 
Administration; EQA, external quality assessment; LR-TF, Laboratory Response 
Task Force; Pan-CoV, pan-coronavirus; EUA, emergency use authorization. 
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